Goals of Treatment for Patients with Metastatic Breast Cancer
- PMID: 16472711
- DOI: 10.1053/j.seminoncol.2005.07.030
Goals of Treatment for Patients with Metastatic Breast Cancer
Abstract
The key goal in the treatment of metastatic breast cancer is to prolong survival, with an emphasis on restricting treatment-related toxicity as much as possible. Despite the plethora of treatment modalities available in metastatic breast cancer, significant survival differences are relatively uncommon. Symptom relief and quality of life are other important, clinically validated measurement instruments. Symptom relief in particular is not used as widely used as it could be, in contrast to lung cancer where it has been proven clinically informative. Finally, time to disease progression is an increasingly used primary endpoint in comparing treatments for metastatic breast cancer; this measure includes both patients who achieve an objective response, and those whose disease may be stabilized with treatment.
Similar articles
-
The use of chemotherapy in metastatic breast cancer.Hematol Oncol Clin North Am. 1989 Dec;3(4):807-21. Hematol Oncol Clin North Am. 1989. PMID: 2481671 Review.
-
[Palliative therapeutic control of tumor progression in patients with metastatic breast cancer].Internist (Berl). 1993 Apr;34(4):340-50. Internist (Berl). 1993. PMID: 7683634 Review. German. No abstract available.
-
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.Crit Rev Oncol Hematol. 2008 Jun;66(3):237-47. doi: 10.1016/j.critrevonc.2007.12.003. Epub 2008 Feb 1. Crit Rev Oncol Hematol. 2008. PMID: 18243010
-
[Cancer chemotherapy based on evidence--metastatic breast cancer].Gan To Kagaku Ryoho. 2000 Jan;27(1):44-51. Gan To Kagaku Ryoho. 2000. PMID: 10660732 Review. Japanese.
-
Advances in chemotherapy for HER2-negative metastatic breast cancer.Chin Clin Oncol. 2018 Jun;7(3):26. doi: 10.21037/cco.2018.06.01. Chin Clin Oncol. 2018. PMID: 30056728 Review.
Cited by
-
Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial.Cancer Immunol Immunother. 2013 Jun;62(6):1053-60. doi: 10.1007/s00262-013-1414-x. Epub 2013 Apr 18. Cancer Immunol Immunother. 2013. PMID: 23595207 Free PMC article.
-
Cancer symptom response as an oncology clinical trial end point.Expert Rev Qual Life Cancer Care. 2018;3(2-3):35-46. doi: 10.1080/23809000.2018.1483193. Epub 2018 Jun 7. Expert Rev Qual Life Cancer Care. 2018. PMID: 31020045 Free PMC article.
-
Single agent versus combination chemotherapy for metastatic breast cancer.Cochrane Database Syst Rev. 2009 Apr 15;2009(2):CD003372. doi: 10.1002/14651858.CD003372.pub3. Cochrane Database Syst Rev. 2009. PMID: 19370586 Free PMC article.
-
Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy.Med Oncol. 2023 Dec 16;41(1):19. doi: 10.1007/s12032-023-02255-8. Med Oncol. 2023. PMID: 38103078 Review.
-
Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer.Patient Prefer Adherence. 2023 Apr 18;17:1049-1062. doi: 10.2147/PPA.S401480. eCollection 2023. Patient Prefer Adherence. 2023. PMID: 37096162 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical